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Summary Hypoxia was assessed in three murine tumour models in vivo by measuring the incorporation of 7-(4'-(2-nitroimidazole-1-yl)-
butyl)-theophylline (NITP), an immunologically identifiable hypoxia marker that binds bioreductively to cells under low-oxygen conditions.
Proliferating cells were labelled in the same tumours by administering the thymidine analogue bromodeoxyuridine (BrdUrd). The relative
hypoxia in each cell cycle phase of cells isolated from tumours was assessed by addition of propidium iodide with analysis by flow cytometry.
There was no relationship between tumour volume and hypoxia in either the anaplastic sarcoma SaF or the poorly differentiated carcinoma
CaNT and only a slight negative correlation in moderately well-differentiated carcinoma Rh. The G1/Go phase contained the greatest number
of aneuploid hypoxic cells (aneuploid hypoxia ranging from less than 1% up to 40%, 38% and 71% in SaF, CaNT and Rh respectively),
although there were significant amounts of hypoxia present in S- and G/M phases for all three tumours examined. However, the highest
proportion of hypoxia occurred in the G/M phase, in which up to 60% of the cells were hypoxic. Simultaneous measurement of hypoxia,
proliferation and DNA content using a novel triple-staining flow cytometry method showed that hypoxic cells could actively participate in the
cell cycle. In addition, the cell cycle distribution of NITP and BrdUrd labelling showed that hypoxic cells could progress through the cell cycle,
although their rate of progression was slower than that of betteroxygenated cells.
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Hypoxic radioresistant regions in some tumours are thought to
reduce the efficacy ofcurative radiotherapy, and the sparing effect
of proliferation of tumour cells during a course of conventional
fractionated radiotherapy can be equivalent to several fractions of
radiation. Proliferation can be studied by incorporation of the
thymidine analogues bromo- and iododeoxyuridine, which can be
identified using a monoclonal antibody with either flow cytometry
analysis or immunohistochemical end points (Begg et al, 1985;
Wilson et al, 1985). Measurements of potential doubling time
(Tpot) are currently being undertaken in a series of trials
comparing conventional with accelerated fractionation, and some
show good evidence that pretreatment cell kinetics can predict
treatment outcome (Wilson et al, 1988; Begg et al, 1992; Corvo et
al, 1995). The degree of hypoxia within a solid tumour is impor-
tant as hypoxic cells will be up to three times more resistant to
radiotherapy than their better oxygenated counterparts (Gray et al,
1953). Meta-analysis of hypoxia-directed treatments has shown
that regimens counteracting hypoxia in tumours are beneficial to
patient survival, particularly in head and neck cancer (Overgaard,
1992). However, before furtherdata can be obtained to support this
conclusion, a reliable method of measuring clinical tumour
hypoxia before treatment must be found. Several techniques are
being developed and have progressed to clinical trial (Stone et al,
1993), with the Eppendorf oxygen microelectrode currently being
the method ofchoice.
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Despite numerous studies of proliferation and hypoxia in
tumours as individual factors affecting treatment outcome, there
has been little investigation of these parameters in combination.
The greater proportion ofprevious work investigated the cell cycle
progress of cells in vitro subjected to extremes of hypoxia
(Pettersen and Lindmo, 1983; Shrieve and Begg, 1985; Amellen
andPettersen, 1991), butfew have attempted to study theirinterac-
tion in vivo. Zeman et al (1993) found that in sequential histolog-
ical sections- of canine tumours there was no systematic
relationship between hypoxia and proliferating cell nuclear
antigen markers. However, clusters of proliferating cells were
reported distal to blood vessels. In a small series of clinical soft-
tissue sarcomas, Nordsmark et al (1996) reported that the fastest
proliferating cells were found in the most hypoxic tumours (char-
acterized by medianpO2), although there was no correlation with
hypoxic fraction. Hypoxic sarcomas are also more likely to
metastasize than better oxygenated tumours (Brizel et al, 1996).
Hypoxic cells accumulate wild-type p53 (Graeber et al, 1994),
which is required for efficient induction of apoptosis by hypoxia
(Graeber et al, 1996). However, this mechanism also provides a
selective pressure for outgrowth of cell lineages with mutated or
deleted p53 in tumours, suggesting that hypoxia may ultimately
select for a more aggressive phenotype.
We have measured hypoxia using bioreductive binding of NITP,
whichconsists ofa2-nitroimidazole with animmunologically recog-
nizable theophylline sidechain. The 2-nitroimidazole component
binds to cellular macromolecules under low-oxygen conditions, and
the bound adducts ofthe probe, in hypoxic cells, can then be identi-
fied and quantified by antibodies raised against the theophylline
(Hodgkiss et al, 1991). S-phase tumour cells, actively synthesizing
DNA in the cell cycle, can be labelled by their incorporation of the
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Figure 1 Typical flow cytometry profiles of cell nuclei prepared from SaF, CaNT and Rh murine tumours 2 h after treatment with NITP and BrdUrd in vivo and
stained for hypoxia (bound NITP metabolites), proliferation (BrdUrd incorporation) and DNA content of cell nuclei, with simultaneous analysis of all three
parameters in the SaF and CaNT tumours using three-colour flow cytometry. The regions on the SaF bivariate distributions represent the following cell
populations: Rl, hypoxic; R2, normoxic; R3, BrdUrd-labelled; R4, BrdUrd-unlabelled. Markers set on the SaF DNA histogram represent; Ml, diploid host cells;
M2, aneuploid tumour cells; M3, Gl; M4, S; M5, G/M
Table 1 Summary of hypoxic fractions in SaF, CaNT and Rh murine
tumours
Total Aneuploid Diploid
hypoxia (%) hypoxia (%) hypoxia (%)
Tumour Mean (range) Mean (range) Mean (range)
SaF 9.9 (< 1-29) 11.6 (< 1-40) 5.5 (< 1-15)
CaNT 6.6 (2-28) 9.9 (< 1-38) 2.7 (< 1-10)
Rh 32.3 (12-67) 35.6 (11-71) 27.8 (10-52)
DNA precursor bromodeoxyuridine (BrdUrd). We have developed a
novel three-colour staining flow cytometry method to measure the
BrdUrd, NITP and DNA content of tumour cells, so that the inter-
action of these three parameters can be investigated (Webster et al,
1995). In this paper, we describe the cell cycle distribution of
hypoxia in three murine tumour models by flow cytometry and
follow the progress ofhypoxic cells through the cell cycle by simul-
taneous evaluation of hypoxia (NITP), proliferation (BrdUrd) and
DNA content.
MATERIALS AND METHODS
Mouse tumour models
The three tumours studied arose spontaneously in the Gray
Laboratory animal colony (Hewitt and Wilson, 1961; Hewitt et al,
1973; Denekamp et al, 1980). The anaplastic sarcoma F (SaF) and
the poorly differentiated mammary adenocarcinoma NT (CaNT)
were transplanted in the syngeneic CBA/Ht Gy F TO mouse. The
moderately well-differentiated Rhodesia adenocarcinoma (Rh)
was transplanted in the syngeneic WHT/Gy F C57B1/10 mouse.
Tumours were grown by inoculating subcutaneously a suspension
of 105 cells in 0.05 ml of 0.9% saline on the dorsum of mice. The
tumours were selected for use, except when otherwise stated, at a
mean diameter of 6 mm, determined using three orthogonal
measurements with callipers. The latent periods for the SaF, CaNT
and Rh tumours were approximately 10 days, 14 days and 6-10
weeks respectively.
Hypoxia and proliferation marker administration
To label hypoxic cells, mice were injected i.p. with a formulation
consisting of0.04 M NITP dissolved in peanutoil with 10% dimethyl
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Figure 2 The relationship between tumour volume and degree of aneuploid
hypoxia in SaF, CaNT and Rh murine tumours labelled with NITP alone.
Spearman's correlation coefficient (rho) for the dependence of aneuploid
hypoxia on tumour volume was 0.139 (P = 0.465), -0.0186 (P = 0.925) and
-0.385 (P = 0.0432) respectively
sulphoxide at a dose of 0.45 ,umol g-' NITP (156 mg kg-', 0.38 ml
per 35-g mouse). Proliferating cells were identified by administering
0.33,mol g-' (100mg kg-') BrdUrd i.p. at a concentration of
0.033 M in 0.9% saline. Animals were sacrificed 2 hours after NITP
injection, tumours excised, weighed and minced finely with scissors.
The tumour fragments were disaggregated into single-cell suspen-
sions by enzyme digestion with 10 ml of 0.02% DNAase I, 0.2%
collagenase IV (Sigma Chemical) in serum-free medium in a
universal container on a rotating wheel for 30 min at 37°C. The cell
suspensions werefiltered through 35-jmnylon mesh andcentrifuged
for 10 min at 1000 r.p.m. Cell pellets were resuspended in 200 jil of
phosphate buffered saline (PBS) andthe singlecells fixedby addition
of 10 ml of 70% ethanol. The fixed cells were stored at least
overnight at4°C.
Hypoxia staining for flow cytometry
The method has been reported previously (Hodgkiss et al, 1991).
Briefly, 106 ethanol-fixed cells were centrifuged in 5 ml of PBS at
2000 r.p.m. for 5 min and resuspended in neat rabbit antiserum to
theophylline (Sigma, Dorset, UK) for 1 h. The cells were washed
with 5 ml of PBS and resuspended in 0.25 ml of PBS containing
0.5%. Tween 20 and 0.1% normal goat serum (PNT) with 25 pl of
IgG fluorescein isothiocyanate-conjugated goat anti-rabbit anti-
serum (Sigma) for 1 h. Cells were washed in 5 ml of PBS and the
pellet resuspended in 2 ml of PBS containing 1 mg ml-' RNAase
and 10 jug ml-' propidium iodide.
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Figure 3 Cell cycle distribution of hypoxia within the aneuploid tumour cells
for the three mouse tumour types (0, Gl; A, S; and *, G/M) labelled with
NITP alone. The data represent individual tumours arranged in ascending
degree of hypoxia
Simultaneous measurement of hypoxia and
proliferation by flow cytometry
The interdependence of cell cycle progression and oxygen status
was studied by labelling hypoxic and proliferating cells according
to two different time schedules. For the first schedule, SaF and
CaNT tumours were labelled in vivo with BrdUrd at the start ofthe
time course and then treated with NITP 2 h before each sacrifice
time. For the second schedule, both NITP and BrdUrd were
administered simultaneously and a range ofsacrifice times used so
that progression of labelled cells through the cell cycle could be
observed.
The method for simultaneous measurementofhypoxiaprolifera-
tion and DNA content has been reported previously (Webster et al,
1995). Briefly, 106 ethanol-fixed cells were washed in PBS,
centrifuged for 5 min at 2000 r.p.m. and the pellet resuspended in
0.2 mg ml' pepsin in 2 M hydrochloric acid for 20 min at room
temperature. The resultant nuclei were washed twice in PBS and
re-suspended in 100 g1 of PNT containing 5 p1 of mouse mono-
clonal to BrdUrd (Dako, Bucks, UK). After 1 h incubation, the
nuclei were washed and the pellet resuspended in 100gl of PNT
with 25 p1 of R-phycoerythrin-conjugated anti-mouse lgG (Dako)
for a further hour. After washing, the pellet was resuspended in
250 pl of undiluted rabbit anti-theophylline antiserum for 1 h. The
final antibody solution, 250 pl ofPNT with 25 pl ofanti-rabbit IgG
FITC conjugate, was added after a further wash and also incubated
British Journal ofCancer (1998) 77(2), 227-234
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Table 2 Analysis of cell cycle distribution of hypoxia (Figure 3) for SaF,
CaNT and Rh murine tumours
Regression analysis Paired t-test
Tumour Comparison Slope Mean P(t)
± s.e.m. difference
SaF G, vs S 0.432 ± 0.018 3.908 < 0.0001
G, vsG2 0.260±0.021 4.827 <0.0001
G2 vs S 0.604 ± 0.037 0.919 < 0.0001
CaNT GI vs S 0.216 ± 0.022 4.431 < 0.0001
G, vs G2 0.241 ± 0.019 3.851 <0.0001
G2vs S 0.881 ±0.105 -0.580 < 0.0005
Rh GI vs S 4.198 ± 0.769 18.106 < 0.0001
G, vs G2 0.143 ± 0.020 17.624 < 0.0001
G2 vs S 0.779 ± 0.149 -0.482 0.1781
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Figure 4 Cell cycle phase-specific hypoxia within the aneuploid tumour
cells for the three mouse tumour types (0, GI; A, S; and *, G/M) labelled
with NITP alone. The data represent individual tumours arranged in
ascending degree of hypoxia
for 1 h. Nuclei were washed for the final time and resuspended
in 2 ml of PBS with 20 gl of 1 mg ml' 7-aminoactinomycin D
solution (Sigma).
Flow cytometry
All samples were run on a Becton Dickinson FACScan with a
single excitation wavelength of 488 nm. Red fluorescence from
Table 3 Analysis of cell cycle phase-specific hypoxia (Figure 4) for SaF,
CaNT and Rh murine tumours
Regression analysis Paired t-test
Tumour Comparison Slope Mean P(t)
± s.e.m. difference
SaF S vs G, 1.232 ± 0.110 -2.365 < 0.0001
G2 vsG, 0.315 ± 0.036 13.570 < 0.0001
G2 vs S 0.215 ± 0.030 15.935 < 0.0001
CaNT S vs G, 0.653 ± 0.057 2.660 < 0.0038
G2 vs G, 0.450 ± 0.038 9.604 < 0.0001
G2 vs S 0.668 ± 0.029 6.944 < 0.0001
Rh S vs G, 0.622 ± 0.130 3.497 0.0433
G2 vs G, 0.625 ± 0.063 16.399 < 0.0001
G2 VsS 0.511± 0.110 12.902 < 0.0001
either propidium iodide or 7-aminoactinomycin D bound to the
DNA was used to select single cells and reject debris and cell
clumps on the basis of their DNA content using the doublet
discrimination mode. Light scatter and fluorescence data were
collected for 104 single cells, with bound NITP (hypoxia) repre-
sented by green fluorescence (FITC), incorporated BrdUrd (prolif-
eration) by orange/red fluorescence (phycoerythrin) and DNA by
red fluorescence (either propidium iodide or 7-aminoactinomycin
D). Compensation was applied for the triple-stained samples to
allow for overlap in the fluorochrome emission spectra and enable
the orange/red fluorescence (phycoerythrin) baseline to approach a
horizontal position.
Statistical analysis
The dependence of hypoxic fraction on tumour volume was
assessed by Spearman's correlation analysis using the JMP statis-
tical package, SAS Institute. The cell cycle phase-dependence of
hypoxia was analysed by regression analysis with a paired t-test
comparison ofdata in the different cell cyclephases, also usingJMP.
RESULTS
Hypoxia related to tumour size
Tumours were selected with geometric mean diameters of 4-
12 mm for assessment of hypoxia. The tumours were analysed
using a DNA histogram and a bivariate distribution of bound
NITP (hypoxia) vs DNA content. Typical profiles for SaF, CaNT
and Rh tumours are displayed in Figure 1, with the appropriate
analysis regions indicated. The hypoxic (RI) and non-hypoxic
(R2) regions were defined using the non-specific background
staining from an appropriate control tumour not treated with
NITP, but excised and taken through the staining procedure. All
three tumour types exhibited both diploid and aneuploid cell
populations, and in these experiments the flow cytometer settings
were adjusted so that the aneuploid tumour cells were always in
approximately the same position on the DNA baseline. The posi-
tion of the diploid G, peak on DNA histograms is identical to
that of the diploid G, cells from murine bone marrow (data not
shown). Based on studies of cell morphology, the predominant
normal cell types were lymphocytes and macrophages (SA Hill,
personal communication). When cultured in vitro, the diploid
cells from both SaF and CaNT tumours fail to proliferate and only
British Journal ofCancer (1998) 77(2), 227-234
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Figure 5 Progression of BrdUrd-labelled cells in murine tumours after labelling with BrdUrd. NITP was administered 2 h before sacrifice. The proportion
of aneuploid BrdUrd labelling in (A) CaNT G1 phase, (B) CaNT G2 phase, (C) SaF G1 phase and (D) SaF G2 phase. *, Oxic cells expressed as oxic
BrdUrd-labelled cells in phase/total oxic BrdUrd-labelled cells; 0, hypoxic cells expressed as hypoxic BrdUrd-labelled cells in phase / total hypoxic
BrdUrd-labelled cells
the aneuploid cells are represented in the culture after a few days
(data not shown).
Using the regions shown in Figure 1, total hypoxia (RI) including
both diploid and aneuploid cells can be calculated. Diploid and
aneuploid hypoxia were estimated from a DNA histogram gated on
RI, with markers (MI and M2 respectively) set for the appropriate
populations. The results for total, aneuploid and diploid hypoxia for
SaF, CaNT and Rh tumours are shown in Table 1. There is a wide
inter- and intra-tumour variation in aneuploid hypoxia with all three
tumour types. The diploid population of cells, consisting of
macrophages, lymphocytes and stromal cells, also showed hypoxia
but to a lesser extent than the aneuploid population, and the mean
fluorescence of the diploid population was lower than that of the
aneuploid cells. This was especially noticeable in the diploid G2IM
population amid the aneuploid S-phase cells of the Rh tumour
(Figure 1).
Figure 2 shows the relationship between aneuploid hypoxia and
tumour volume. At these macroscopic sizes, there was no correla-
tion between volume and hypoxia in the Saf and CaNT tumours
(Spearman's correlation coefficient rho = 0.139, P = 0.465 and
-0.0186, P = 0.925), respectively, while the Rh tumour showed a
slight trend that wasjust significant (rho = -0.385, P = 0.0432) for
hypoxia to fall with increasing volume.
Cell cycle distribution of hypoxia
Analysis of the distribution of hypoxia within the cell cycle was
carried out by setting markers (M2 to M5) on DNA histograms
gated on the hypoxic and oxic cells (Figure 1). Hypoxia was
present throughout the cell cycle (Figure 3 and Table 2), and the
G1/Go phase contained the greatest number of hypoxic cells and
was significantly different from the S- and G2 phases (Table 2). In
British Journal of Cancer (1998) 77(2), 227-234
A C
I
80
a-
U)
= 60 a) 0
0
co
-6 40
0.
=0 20
c
0
60
-
U)
0)
c'j 40 ~0 cm4
'a) A 0)
.0
co
-6
D
lm
V 20
0 CL
:3
I
L
I
ro
I I I I I
,
0CancerResearch Campaign 1998232 L Webster etal
A
80 F
0-
CD
m
co
C2 V
V2
0 0
60 F
//o %
. a _- _'
*0i 0
0 40 F
201[-
20 L
B
50 1
0
I- I I I I
0
40 F
0)
Cl
.0
Cu
0)
mS
30 F
20 F
10 F
0
/ '
ago .' 0
0O 0 0 .' - 4
0
*
.
1
0
10 20
Time (h)
Figure 6 Progression of BrdUrd-labelled cells in SaF tumours after
simultaneous labelling with NITP and BrdUrd. The proportion of aneuploid
BrdUrd labelling in (A) G1 phase, (B) G2 phase. *, Oxic cells expressed as
oxic BrdUrd-labelled cells in phase/total oxic BrdUrd-labelled cells; 0,
hypoxic cells expressed as hypoxic BrdUrd-labelled cells in phase/total
hypoxic BrdUrd-labelled cells
the SaF GI/Go hypoxia ranged from < 1% to 24% in the CaNT
from < 1% to 23% and in the Rh from < 1% to 58% of the
aneuploidhypoxic population. This is notsurprising as, in all three
tumours, GI/Gorepresents 40% of the total cell population. In all
three tumour types, when hypoxia was present, S- and G2/M
phases also contained significant numbers ofhypoxic cells.
However, calculation of the proportion of hypoxic cells within
each individual phase of the cell cycle showed that, although the
greatest number of hypoxic cells resided in G1/Go, the phase of
the cell cycle with the highest proportion of hypoxia was G/M
(Figure 4 and Table 3), with typically a two-fold lower proportion
of hypoxic cells within the GJG, and S-phases. This effect was
most marked in the SaF tumour, but similarpatterns werealso seen
in the CaNT and Rh tumours, and ineach caseG2was significantly
different from the G, and S-phases (Table 3).
Cell progression studies
Analysis of cell progression in CaNT and SaF tumours labelled
with NITP and BrdUrd was carried out using the regions illus-
trated in Figure 1, set on bivariate distributions of hypoxia or
proliferation vs DNA content. From these, gated DNA histograms
were created to includeonly cells labelled with eitherboth BrdUrd
and NITP (RI and R3) or cells labelled with BrdUrd and not with
NITP (R2 and R3). Markers (M2 to M5) set on these DNA
histograms allowed the number of cells within each phase of the
aneuploid cell cycle to be calculated for both labelled subgroups.
The stromal host cells were not included in this analysis, and
previous work has shown that the majority ofthese cells show little
progression.
Figure 5 shows the time dependence of BrdUrd labelling in the
GIand G2 phases of the cell cycle in hypoxic and normoxic aneu-
ploid cells from CaNT and SaF solid tumours that were labelled in
vivo with BrdUrd at the start of the experiment and with NITP
during the 2-h period before each time point. Movement of
BrdUrd-labelled cells through mitosis intoGI occurs more rapidly
in the normoxic population than in the hypoxic cells (Figures 5A
and C) in both tumour types, and there is acorresponding delay in
progression of labelled cells out of G2 in hypoxic compared with
normoxic cells, although this delay is more obvious in CaNT
tumours (Figure SB) than in SaF tumours (Figure SD). In both
tumour types, 10-20% of both hypoxic and normoxic BrdUrd-
labelled cells that enter G2 show little cell cycle progression over
the 30-h time course oftheexperiment.
Figure 6 shows the time dependence ofBrdUrd labelling in SaF
tumours, in which both proliferating S-phase cells and hypoxic
cells were labelled with both BrdUrd andNITP, respectively, at the
start of the experiment. Both incorporated BrdUrd and bound
NITP could be reliably identified in cells from tumours 28 h after
administration, and the pattern of progression of labelled cells
through the cell cycle was broadly similar to that seen with
staggered proliferation and hypoxia marker administration. The
BrdUrd-labelled cells within each phase of the cell cycle were
classified as hypoxic (NITP binding) or oxic (no NITP binding).
Each cell cycle phase was expressed as a percentage of the total
BrdUrd-labelled cells so that the values were unaffected by
progression ofunlabelled cells. The time course ofprogression of
BrdUrd-labelledcells through all threephases ofthe cell cycle was
similar. However, progression of hypoxic cells through mitosis
into G1 was slightly delayed compared with that ofnormoxic cells
(Figure 6A), and this was probably related to a transient build-up
ofhypoxic cells in G2 (Figure 6B) before passing through mitosis.
A proportion (10%) of BrdUrd-labelled cells appear to arrest
permanently in G2 rather than progressing through mitosis.
DISCUSSION
Metabolic binding of NITP has a similar dependency on oxygen
concentration to that of radiosensitivity (Hodgkiss et al, 1991).
The K-value for binding (1400 p.p.m. oxygen) compared with the
K-value (3800 p.p.m. oxygen) for radiosensitivity under identical
conditions suggests that NITPbinding requires slightly more strin-
gent hypoxia than that needed for radioresistance. The majority of
the NITP binding observed is therefore to relatively hypoxic
radioresistant cells at oxygen tensions below the K-value for
radiosensitivity. Tumours contain gradients of oxygen (and other
nutrients) and the concept of hypoxic and well-oxygenated popu-
lations is an oversimplification. The population defined as hypoxic
is probably heterogeneous in both the level and duration of low
oxygen tensions to which the individual cells have been subjected.
Some of the NITP binding may reflect different stringencies of
hypoxia or, alternatively, may reflect acute variations in oxygen
tension during the period of drug binding; it is not possible to
distinguish between these alternatives at present.
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Tumour size
The hypoxic fraction is thought to consistently increase with
tumour size as the tumour grows from a microscopic to a macro-
scopic lesion, in which some cells are further from a blood capil-
lary than the diffusion distance of oxygen through tissues. Within
the macroscopic range, the relationship of tumour size to hypoxic
fraction is less clear (Moulder and Rockwell, 1984). However,
when some specific tumours were compared at different sizes,
there was a trend for the hypoxic fraction to increase as size
increased, although this was not true for all tumour types (Stanley
et al, 1977; Siemann, 1980; Wallen et al, 1980; Okunieff et al,
1986; Fu etal, 1990). Overthe size range of4- to 12-mmdiameter,
SaF, CaNT and Rh tumours showed no correlation between size
and hypoxic fraction measured by flow cytometric analysis of
bioreductively bound NITP abducts (Figure 2). The range in
hypoxic fraction was large, even for tumours ofsimilar diameter or
weight. Inter-tumoral differences in hypoxic binding are not
related to differences in drug (NITP) delivery (Hodgkiss et al,
1995) or to poor drug distribution, as immunostaining of sections
of large tumours (10-mm diameter) shows hypoxia to be distrib-
uted throughout the tumour section, although with a variable
pattern depending on the structure of the tumour (unpublished
data). The three tumours selected show a corded pattern (CaNT;
Hodgkiss et al, 1991), a patchy distribution (SaF) and a random,
highly hypoxic pattern (Rh). The estimation by flow cytometry of
mean hypoxic fractions of 11.6%, 12.9% and 35.6% for the SaF,
CaNT and Rh tumours, respectively, is supported by the greater
density and more widespread staining in sections ofthe Rh tumour
compared with sections of the other tumours.
Hypoxia and cell cycle
Profiles of hypoxic cells produced by NITP and flow cytometry
showed that most hypoxic cells were in the GI/Go population,
although hypoxia occurred throughout the cell cycle (Figure 3 and
Table 2). Most ofthe cells in tumours tend to be in GI/Go and the
predominance ofG, cells in the hypoxic subpopulation probably
reflects this. Cells are thought to arrest in GI as they move away
from blood vessels, becoming hypoxic and nutritionally deprived
(Tannock, 1968; Hirst and Denekamp, 1979), and finally enter the
quiescentGophase. Similar observations have been made in spher-
oids in which theproportion ofnutritionally deprived cells and the
percentage ofGI cells increases with size, while the proportion of
those in the S- and G2 phases decreases (Sutherland et al, 1986).
However, our observation ofsignificant numbers ofhypoxic S and
G/M cells is also supported by other investigators (Pallavicini et
al, 1979; Siemann and Keng, 1988).
Within each cell cycle phase (defined by DNA content) in SaF,
CaNT and Rh tumours, thehighestproportion ofhypoxic cells was
located within G2 (Figure 4 and Table 3). Most in vitro cell cycle
studies have shown that induction ofhypoxia produces either total
arrest of the cell cycle or cell cycle-specific arrest (Pettersen and
Lindmo, 1983; Shrieve and Begg, 1985; Amellem and Pettersen,
1991). Survival studies on different components of the cell cycle
have shown S-phase to be the most sensitive to hypoxic treatment,
with sensitivity slightly reduced in G1 and greatly reduced in G2
(Spiro et al, 1984). Entry of cells into S is often blocked with an
accumulation at the Ga/S border and cells can be either totally
arrested in S such that no further DNA synthesis occurs, or
progress slowly through S-phase with synthesis of DNA over a
prolonged period (Pettersen and Lindmo, 1983). Cells in G2/M
have been reported to be insensitive to hypoxia, progressing
through mitosis to Gp, where arrest may occur. In the in vivo
studies presented here, a high proportion of hypoxic cells in G2
may have completed a hypoxic S-phase, perhaps with a reduced
fidelity of DNA synthesis, and then progress slowly or are unable
to continue through mitosis. Wilson et al (1994) reported that
20-25% ofcells in untreated BrdUrd-labelled cells in SaF and Rh
tumours arrested in G2 in the first cycle. Some of these G2 cells
may no longer be clonogenic and may be committed to die from
signals related to hypoxia or nutritional status.
Measurement of proliferation and hypoxia
Following BrdUrd-labelled cells through the cell cycle and
assessing their hypoxia at time intervals showed that cells actively
progressing through the cell cycle could become hypoxic (Figure
5) and that their progression was delayed relative to the better
oxygenated component. The hypoxic status of cells can only be
determined at the time of labelling, and reoxygenation at other
times can not be excluded and may account for some of the cell
cycle progression. Slower progression of hypoxic compared with
normoxic cells through G2 leads to a temporary accumulation of
hypoxic G2 cells in CaNT tumours (Figure 5B) and delays their
entry into G, (Figure 5A). Similar but less marked trends are also
observed in SaF tumours, in which progression of hypoxic cells
appears to be relatively slow. In both tumour types a proportion of
G2 cells became permanently arrested, and this appeared to be
more closely related to oxygenation status in CaNT rather than in
SaF tumours, in which other factors may be more important. It
may be hypothesized that progression ofthe hypoxic cells in both
tumour types is delayed because ofdeprivation ofoxygen or other
nutrients, but in these experiments chronically and acutely hypoxic
cells can not be distinguished.
Labelling SaF tumours simultaneously with proliferation
(BrdUrd) and hypoxia (NITP) markers and following the progress
of this BrdUrd-labelled cohort through the cell cycle supported
these observations (Figure 6). The presence of significant NITP
binding 28 h after labelling demonstrated persistence of hypoxic
cells in these tumours. Some progression through the cell cycle of
these hypoxic S-phase cells was observed during this time. Slower
progression ofhypoxic compared with normoxic cells through G2
led to a temporary accumulation of hypoxic G2 cells 8 h after
labelling (Figure 6B) and delayed their entry intoG, (Figure 6A).
The observed delay in entry of hypoxic compared with oxic cells
into G0 was much shorter after simultaneous compared with stag-
gered administration of proliferation and hypoxia markers and
may be evidence for reoxygenation ofpart ofthe hypoxic popula-
tion during the time course ofthe experiment.
The G2 block seen after both staggered and simultaneous
labelling with hypoxia and proliferation markers could reflect
hypoxic S-phase DNA synthesis, which may increase the proba-
bility offaulty replication ofDNA. p53 is induced by hypoxia and
DNA damage and is responsible for cell cycle arrest in both G0
(Cox and Lane, 1995; Shimamura and Fisher, 1996) and G2
(Stewart et al, 1995). A G2 delay would allow post-replication
repair to occur, with sectoring of genetically damaged cells to
undergo apoptosis or necrosis. A G2block may also create a reser-
voirofpre-mitotic cells. In vitro modelling has shown that cells do
not tend to enter DNA synthesis unless they have a good nutrient
and oxygen supply. Gelfant (1977) also showed in vivo that mouse
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epithelium contained a number ofcells permanently arrested inG2
that remained there for at least several months. These cells were
activated when the tissue was injured to immediately repopulate
the area through mitosis, while othercells initiated DNA synthesis.
A reservoir ofG2 cells in unfavourable (hypoxic) conditions could
allow rapid repopulation if more favourable conditions within the
tumour were restored.
In this study of cell cycle progression and hypoxia in vivo,
evidence has been presented to show that hypoxic cells in tumours
can not only actively synthesize DNA, but that some cell cycle
progression is possible under hypoxic conditions, although at a
slower rate than in better oxygenated cells. Hypoxic S-phase cells
exhibit delayed progression through G2 into mitosis, and this may
indicate a cell cycle checkpoint in G2 at which the fidelity ofDNA
synthesis in hypoxic or nutrient-deprived environments is moni-
tored or DNA repair carried out. These studies demonstrate an
approach towards elucidating the complex interactions between the
hypoxic and proliferating compartments in tumours, which will
help to identify the mechanisms involved in cell cycle regulation.
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